%0 Journal Article
%T Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study
%A David Castro-Diaz
%A Pilar Miranda
%A Francisco Sanchez-Ballester
%A Isabel Lizarraga
%A Daniel Arum¨ª
%A Javier Rejas
%J BMC Urology
%D 2012
%I BioMed Central
%R 10.1186/1471-2490-12-19
%X A post-hoc analysis of data from a retrospective, cross-sectional and observational study was performed in a cohort of 748 OAB adults patients (OAB-V8 score ¡Ý8), who switched to fesoterodine from their first tolterodine-ER-based therapy within the 3¨C4£¿months before study visit. Effect of fesoterodine doses (4£¿mg vs. 8£¿mg) and patient age (<65£¿yr vs. ¡Ý65£¿yr) were assessed. Patient reported treatment benefit [Treatment Benefit Scale (TBS)] and physician assessment of improvement with change [Clinical Global Impression of Improvement subscale (CGI-I)] were recorded. Treatment satisfaction, degree of worry, bother and interference with daily living activities due to urinary symptoms were also assessed.Improvements were not affected by age. Fesoterodine 8£¿mg vs. 4£¿mg provides significant improvements in terms of treatment benefit [TBS 97.1% vs. 88.4%, p£¿<£¿0.001; CGI-I 95.8% vs. 90.8% p£¿<£¿0.05)], degree of worry, bother and interference with daily-living activities related to OAB symptoms (p <0.05).A change from tolterodine ER therapy to fesoterodine with dose escalation to 8£¿mg in symptomatic OAB patients, seems to be associated with greater improvement in terms of both patient-reported-treatment benefit and clinical global impression of change. Improvement was not affected by age.Overactive bladder (OAB) is a lower urinary tract disorder characterized by urgency with or without urge incontinence, often with increased daytime frequency and nocturia [1-4]. The prevalence of OAB increased with age [5-8]. In Spain, the EPICC study showed that the prevalence of OAB, previously estimated in adults ¡Ý40£¿years of age at 21.5% [9], was 5.9% for women aged 25¨C64, 4.6% for men aged 50¨C65 and 38.5% for institutionalized people over 65 [10]. The symptoms associated with OAB can significantly affect the psychological, social, occupational, domestic, and sexual aspects of those who suffer from it [11]. As a result, OAB has a negative impact on the patient¡¯s quality of life [12,13]. Des
%K Overactive bladder
%K Fesoterodine
%K Tolterodine ER
%K Dose escalation
%K Age
%K Patient-reported treatment benefit
%U http://www.biomedcentral.com/1471-2490/12/19